Insider Transactions in Q1 2024 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
260
+0.26%
|
$17,940
$69.2 P/Share
|
|
Mar 31
2024
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
79
+0.81%
|
$5,451
$69.2 P/Share
|
|
Mar 20
2024
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.77%
|
$360,000
$18.56 P/Share
|
|
Mar 11
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,712
-5.53%
|
$241,280
$65.97 P/Share
|
|
Mar 11
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,345
-7.04%
|
$477,425
$65.96 P/Share
|
|
Mar 11
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,345
-91.57%
|
$484,770
$66.26 P/Share
|
|
Mar 11
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
10,121
-95.16%
|
$667,986
$66.55 P/Share
|
|
Mar 11
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
20,565
-0.48%
|
$1,357,290
$66.21 P/Share
|
|
Mar 10
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+23.8%
|
-
|
|
Mar 10
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+16.55%
|
-
|
|
Mar 10
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+50.0%
|
-
|
|
Mar 10
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,121
+50.0%
|
$566,776
$56.73 P/Share
|
|
Mar 10
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,565
+1.88%
|
-
|
|
Mar 07
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,450
-15.44%
|
$425,700
$66.6 P/Share
|
|
Mar 07
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,132
-16.66%
|
$866,712
$66.66 P/Share
|
|
Mar 07
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,132
-99.16%
|
$866,712
$66.47 P/Share
|
|
Mar 07
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
13,132
-74.8%
|
$866,712
$66.6 P/Share
|
|
Mar 07
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,712
-1.88%
|
$2,686,992
$66.65 P/Share
|
|
Mar 06
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+36.73%
|
-
|
|
Mar 06
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+50.0%
|
-
|
|
Mar 06
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+50.0%
|
-
|
|
Mar 06
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,712
+3.6%
|
-
|
|
Mar 06
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,132
+23.47%
|
-
|
|
Feb 27
2024
|
Robert L Van Nostrand |
SELL
Open market or private sale
|
Direct |
20,000
-42.22%
|
$1,440,000
$72.92 P/Share
|
|
Feb 27
2024
|
Robert L Van Nostrand |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+40.31%
|
$360,000
$18.56 P/Share
|
|
Feb 26
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
13,337
-77.96%
|
$920,253
$69.43 P/Share
|
|
Feb 26
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,882
+50.0%
|
$211,752
$36.89 P/Share
|
|
Feb 26
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,907
-66.21%
|
$545,583
$69.4 P/Share
|
|
Feb 26
2024
|
Joel S Marcus |
SELL
Open market or private sale
|
Direct |
26,328
-14.69%
|
$1,790,304
$68.83 P/Share
|
|
Feb 26
2024
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
36,757
+24.57%
|
$1,801,093
$49.47 P/Share
|
|
Feb 26
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,907
-5.65%
|
$545,583
$69.87 P/Share
|
|
Feb 26
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,112
-11.31%
|
$287,840
$70.19 P/Share
|
|
Feb 26
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
22,590
-0.71%
|
$1,558,710
$69.32 P/Share
|
|
Feb 23
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,455
+50.0%
|
-
|
|
Feb 23
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,907
+50.0%
|
-
|
|
Feb 23
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,907
+17.37%
|
-
|
|
Feb 23
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,907
+36.76%
|
-
|
|
Feb 23
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,590
+2.06%
|
-
|
|
Feb 02
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
33,885
-1.58%
|
$2,270,295
$67.06 P/Share
|
|
Feb 02
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,860
-96.99%
|
$782,760
$66.77 P/Share
|
|
Feb 02
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
11,183
-99.17%
|
$738,078
$66.98 P/Share
|
|
Feb 02
2024
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,860
-15.39%
|
$794,620
$67.08 P/Share
|
|
Feb 02
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,167
-29.94%
|
$413,189
$67.09 P/Share
|
|
Feb 01
2024
|
Sharon Mates Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,885
+3.03%
|
-
|
|
Feb 01
2024
|
Michael Halstead EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
11,860
+50.0%
|
-
|
|
Feb 01
2024
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,183
+50.0%
|
-
|
|
Feb 01
2024
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,860
+22.2%
|
-
|
|
Feb 01
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,860
+50.0%
|
-
|
|
Jan 18
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
67,917
-3.04%
|
$4,414,605
$65.72 P/Share
|
|
Jan 18
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
67,917
+5.73%
|
$1,086,672
$16.86 P/Share
|